With a Large Patient Population, High Medical Need, and a Difficult Development Path, the Sepsis Drug Market is Commercially Attractive but Risky

WALTHAM, Mass., May 9 /PRNewswire/ — Decision Resources, Inc., one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the severity of sepsis, along with the dearth of upcoming competition and lack of safe and effective therapies targeting the systemic inflammatory response, makes this indication commercially attractive. According to the report entitled Sepsis — Search for a Safe Drug Targeting the Inflammatory/Coagulation Cascade, given the drawbacks of Lilly’s Xigris (significant side effects, contraindications), novel agents that can target the inflammatory/coagulation cascade and offer a safer profile are needed.

The report also finds that there is significant risk associated with entering the market.

“The complex nature of sepsis pathophysiology and the heterogeneous population make clinical development in sepsis a risky undertaking for biopharmaceutical manufacturers,” says John Lebbos, M.D., analyst at Decision Resources. “Indeed, several highly promising approaches (anti-tumor necrosis factor, antithrombin III, antiplatelet activating factor, tissue factor pathway inhibitor) have failed in clinical trials.”

About Sepsis — Search for a Safe Drug Targeting the Inflammatory/Coagulation Cascade

Sepsis — Search for a Safe Drug Targeting the Inflammatory/Coagulation Cascade covers the current state of the sepsis drug market. The report includes the following:

   * Analysis of the sepsis market focused on the diagnosed/drug-treated     populations, patient/market share projections, cost per day, and     compliance expectations.    * High prescribing physicians identify the specific clinical trial end     points that most impact prescribing and project the patient share such     an advance would capture.    * A ten-year forecast that builds on drug development advances and     physician acceptance balanced by payer constraints and generic     introductions.   

The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com  

Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,emarshall@dresources.com

Web site: http://www.decisionresources.com/